-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M and A In Pharmaceutical Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract...
-
Company Profile
Teligent Inc – Company Profile
Teligent Inc (Teligent), formerly IGI Laboratories Inc, is a specialty generic pharmaceutical company that markets and sells a portfolio of generic pharmaceutical products under its own label and private label to other pharmaceutical companies. The company offers products in topical, injectable and other high-barrier dosage forms. It offers generic topical and generic and branded generic injectable pharmaceutical drugs in the US and Canada. It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic markets. The...
Add to Basket -
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2020 PharmSource Edition
This report is the 10th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Track & Monitor
CMO Scorecard – Outsourcing of NDA Approvals and CMO Performance – 2019 PharmSource Edition
This report is the 9th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.
-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.